CBD companies continue to make advances in the health and wellness subcategory with new product launches, distribution agreements, and ongoing clinical trials.
California-based CBD product maker CV Sciences has announced the launch of a full line of clinical-strength CBD products available only from doctors in the United States.
The company said the products will be backed by published research, randomized controlled trials, and a post-market safety review. It added that they are designed to fit into existing care plans and are available in roll-on, liquid and softgel formulations.
“Alternative medicine use is becoming more common as consumer preferences shift towards natural, herbal remedies for a range of conditions. We are excited to bring ProCBD to market and to partner with health professionals who are seeking science-based, natural alternatives for their patients, “said Joseph Dowling, CEO of CV Sciences.
Similarly, Canadian nutraceutical company NeutriSci International has focused on the health and wellness market. It said it intends to launch its broadband CBD tablet brand Tabletz in Japan.
The company plans to manufacture and distribute several hundred thousand units of the tablet sticks in a number of retail locations in Japan, where, according to NeutriSci, consumers are strong advocates of plant-based health and wellness products. The company said it hadn’t finalized the details of in-store distribution, but previously listed 7-Eleven, KK Lawson and Biople as potential Japanese retailers.
“We believe we can reach a significant share of the CBD market in Japan. There is currently no comparable product on the market, ”said Glen Rehman, CEO of NeutriSci.
The product is now waiting in the port of entry for customs classification (HS code). It is sold in three and seven tab sticks and comes in three flavors – lemon, berry, and mint.
“With product approvals, a pause in new application approvals at the ministerial level, combined with the features and benefits of the product itself, plus a strong distribution network and positive initial consumer feedback, there is strong confidence that Tabletz can do one of the best-selling CBD brands of its kind in Japan be, ”said Rehman.
NeutriSci is also working on the upcoming launch of a large bottle format (35 14 mg tablets totaling 490 mg CBD) from Tabletz, which will also be available in the same three flavors and is expected to be part of a second order for the Japanese market.
The company had previously announced that it would officially launch the Tabletz brand in the Japanese market in November 2020, but this has been delayed for reasons that are currently unclear. It just completed a round of funding that sold nearly 2.5 million shares at $ 0.15 each to raise $ 370,050 to be used for production runs related to its product launch in Japan.
And in Europe, UK health and wellness chain Holland & Barrett has signed distribution agreements with European manufacturer of CBD and hemp oil products, Reakiro, and has expanded its ongoing distribution relationship with World High Life’s Love Hemp brand.
Reakiro’s range of full spectrum products includes oils, sprays, a raw hemp extract pen and gelcaps in a wide range of strengths and will appear in all 737 UK stores and online.
“We are very proud to partner with Holland & Barrett, the leading health and wellness retailer,” said Stuart McKenzie, CEO of Reakiro. “Holland & Barrett and Reakiro share the same values - providing the highest quality natural health products to people around the world. We look forward to a productive and long-term partnership with you. “
Love Hemp has launched another ten products, including sprays and capsules, in 880 Holland & Barrett stores in the UK and Ireland and made the products available through the health food store’s website. These include various strengths from 600 mg to 3,000 mg of CBD.
Love Hemp and Holland & Barrett have also launched a consumer education and awareness program on CBD in 400 of their stores to help build consumer knowledge about the benefits of CBD. It is unclear what paid agents could say who did not violate the ban on marketing health claims.
“This is a significant relationship not only in terms of scale, but also because Love Hemp and Holland & Barrett implemented a groundbreaking education and awareness program designed to educate consumers about the benefits of CBD,” said Tony Calamita, CEO by Love Hemp. “It is important to invest with partners like Holland & Barrett to build consumer knowledge and confidence so that they know they are buying credible products from credible retailers.”
Meanwhile, the Australian company Avecho Biotechnology has joined a medical cannabis study that, if successful, could open up the range of CBD products on the market and increase their therapeutic potential.
The CA Clinics Observational Study (CACOS) will, for the first time, test the performance of Avecho’s oral CBD formulation on human patients to continue previous successful demonstrations of the product’s ability to aid the absorption of CBD drugs in animals.
“This study is an important step in gathering real-world evidence from patients,” said Paul Gavin, CEO of Avecho. “The entry into an existing test framework offers Avecho both cost and speed advantages.”
If the product’s effectiveness is demonstrated in human patients, Avecho believes it could create room for more CBD products on the market at lower cost and with greater therapeutic potential.
“The design of the observational study enables the product to be used in a range of indications that may prioritize certain indications for further development or eliminate indications where treatment is less effective,” said Gavin.
The company will use the study to gather feedback on the performance of the product from patients currently using medical cannabis to treat a range of indications. Performance is compared to commonly prescribed CBD formulations.
The CACOS study aims to recruit 3,000 patients through a network of medical cannabis prescribing clinics and will use questionnaires to examine the side effects, dosage response and treatment satisfaction of medical cannabis formulations on patient health.
The data generated will help shape the future development of Avecho’s pharmaceutical CBD products while also exploring the potential for Australian SAS-B prescribing.
Recruitment for the CACOS trial will begin immediately and will last through 2021.
CBD intelligence provides impartial, independent and world-class market and regulatory analysis, law enforcement and quantitative data for the cannabidiol (CBD) sector worldwide.
We offer our clients the tools to navigate this fast-moving sector, adjust their business strategy, optimize resources and make informed decisions. In addition, we offer tailor-made research and consulting support.